Winkel Mirjam Gauri, Stortecky Stefan, Wenaweser Peter
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Heart Clinic Hirslanden Zurich, Zurich, Switzerland.
Front Cardiovasc Med. 2019 Dec 18;6:179. doi: 10.3389/fcvm.2019.00179. eCollection 2019.
Degenerative heart valve disease is associated with significant morbidity and mortality and healthcare expenditures. Transcatheter heart valve repair and replacement has introduced a fundamental change in the therapeutic management and transcatheter aortic valve replacement (TAVR) has gained substantial popularity. Favorable results from randomized trials and large real world registries lead to TAVR being considered a standard procedure with high rates of procedural success and low rates of peri-procedural complications. This article aims to review the past evolution, summarize the available evidence, discuss current indications and limitations and venture a glimpse into the future of percutaneous interventions for aortic valve disease.
退行性心脏瓣膜病与显著的发病率、死亡率及医疗保健支出相关。经导管心脏瓣膜修复和置换术给治疗管理带来了根本性变革,经导管主动脉瓣置换术(TAVR)已广受欢迎。随机试验和大型真实世界注册研究的良好结果使TAVR被视为一种具有高手术成功率和低围手术期并发症发生率的标准手术。本文旨在回顾过去的发展历程,总结现有证据,讨论当前的适应症和局限性,并展望主动脉瓣疾病经皮介入治疗的未来。